ArticleAmerican journal of translational research2026
Efficacy of neoadjuvant novel hormonal therapy combined with radical prostatectomy for high-risk prostate cancer and analysis of biochemical recurrence-free survival.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of neoadjuvant novel hormonal therapy (NHT) combined with radical prostatectomy (RP) in patients with high-risk prostate cancer (HRPCa), and identify independent influencing factors for 3-year biochemical recurrence-free survival (BCRFS).
methodsA total of 420 patients with HRPCa treated between 2017 and 2022 were enrolled and retrospectively analyzed. All patients were divided into training (n=294) and validation (n=126) sets at a 7:3 ratio. Each cohort was further subdivided into the combination group and the RP-alone control group. Relevant clinical data were collected, and Cox regression analysis, nomogram construction and receiver operating characteristic (ROC) curve analysis were performed.
resultsBaseline data were well balanced between the sets and the groups (all P>0.05). The combination group presented significantly lower positive surgical margin rate (8.7% vs 31.9%), lymph node metastasis rate (10.7% vs 27.8%) and 3-year biochemical recurrence (BCR) rate (12.0% vs 30.6%, all P<0.001), as well as longer BCRFS (34.81±3.27 months vs 33.14±5.67 months, P=0.002). No significant difference was observed in postoperative complication rate between the two groups (4.0% vs 6.9%, P=0.266). Preoperative prostate-specific antigen ≥28.285 ng/mL, Gleason score ≥8.5, positive surgical margin and lymph node metastasis were independent risk factors for BCR (all P<0.003). The area under the ROC curve of the combined prediction model was 0.881 in the training cohort and 0.876 in the validation cohort.
conclusionNHT combined with RP can improve clinical outcomes of HRPCa without increasing postoperative complications. The four above-mentioned indicators can effectively predict the 3-year BCR risk of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.